Biotechnology initial public offerings have continued to price at a slow pace in the first three months of 2026, but the amount raised in their initial share sales has soared compared to previous years. Biopharma companies collectively banked $1.7 billion in IPOs in the first quarter of 2026, the most of any quarter since 2021, according to BioPharma Dive data. Three of those companies raised more than $300 million, a benchmark rarely seen since the sector’s peak in 2021. So far in 2026, biotechs have raised a median of $287.5 million, more than double what was seen during January and March of last year and the highest of any quarter since 2021.
Read the full article: Biotech IPOs Stayed at Slow Pace, but Grew Larger in the First Quarter of 2026 //
Source: https://www.biopharmadive.com/news/biotech-ipo-performance-q1-2026/815879/